Protocol Ledger

NCT07142252 · Phase II · RECRUITING

Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus

Interventional Phase II clinical trial protocol NCT07142252 sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-05-14 Enrollment: 66 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07142252
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)66 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07142252
Protocol FieldVerified Registry Value
NCT IdentifierNCT07142252
Consolidated Lead SponsorNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment66 participants (ESTIMATED)
Registered Start Date2026-05-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI